Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13829957 | 1.00 | CYP3A4 (0.43) | CYP3A4ADRB3ADRA2BADRA2C | |
| SCHEMBL17732634 | 0.88 | CYP3A4 (0.46) | CYP3A4 | |
| SCHEMBL13829909 | 0.88 | CYP3A4 (0.46) | CYP3A4 | |
| SCHEMBL14927493 | 0.88 | CYP3A4 (0.46) | CYP3A4 | |
| SCHEMBL13829670 | 0.87 | CYP3A4 (0.55) | CYP3A4 | |
| SCHEMBL15681102 | 0.87 | CYP3A4 (0.55) | CYP3A4 | |
| SCHEMBL18827781 | 0.87 | CYP3A4 (0.49) | CYP3A4 | |
| SCHEMBL13830365 | 0.85 | CYP3A4 (0.51) | CYP3A4 | |
| SCHEMBL16487845 | 0.85 | CYP3A4 (0.51) | CYP3A4 | |
| SCHEMBL3373243 | 0.85 | ADRB3 (0.42) | CYP3A4ADRB3ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9527885-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-27 | — | — | US | disclosed |
| EP-2909205-B1 | 9-METHYL SUBSTITUTED HEXADECAHYDROCYCLOPROPA(E)PYRROLO(1,2-A)(1,4)DIAZACYCLOPENTADECINYL CARBAMATE DERIVATIVES AS NON-STRUCTURAL 3 (NS3) PROTEASE INHIBITORS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-23 | — | — | EP | disclosed |
| US-9499550-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-11-22 | — | — | US | disclosed |
| EP-2705049-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-19 | — | — | EP | disclosed |
| US-20150284391-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-08 | — | — | US | disclosed |
| US-20150125422-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-05-07 | — | — | US | disclosed |
| US-8957203-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-02-17 | — | — | US | disclosed |
| US-20130115190-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150125422-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, GOT1 | CYP3A4 455/4885ADRB3 3229/4885ADRA2B 3268/4885 |
| US-20150284391-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, GOT1 | CYP3A4 455/4885ADRB3 3229/4885ADRA2B 3268/4885 |
| US-20130115190-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, GOT1 | CYP3A4 455/4885ADRB3 3229/4885ADRA2B 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.